Hemodynamic Monitoring for Heart Failure Patients

Academic Content

Program Overview

Faculty Presentations

Introduction Akshay S. Desai MD, MPH William T. Abraham, MD

Faculty Roundtable Discussion

Presentation Notes and References

Current Activity

William T Abraham, MD, FACP, FACC, FAHA, FESC
Director, Division of Cardiovascular Medicine
Professor of Internal Medicine, Physiology and Cell Biology
The Ohio State University Wexner Medical Center
Deputy Director, Davis Heart and Lung Research Institute
The Ohio State University
Columbus, Ohio

Fig. 01 -

Presentation Title

Fig. 02 -

CHAMPION Trial Design

Fig. 03 -

PAP Measurement System

Fig. 04 -

CHAMPION PA Target Pressures

Fig. 05 -

Clinical outcomes

Fig. 06 -

PAP-M: Reduces hospitalizations

Fig. 07 -

PAP-M: Benefits and comorbidities

Fig. 08 -

PAP-M: Better than GDMT

Fig. 09 -

PAP-M: Lowers mortality

Fig. 10 -

CHAMPION lowers 30-day readmissions

Fig. 11 -

CHAMPION: Effect on CMS HRRP

Fig. 12 -

CHAMPION: Longitudinal analysis(1)

Fig. 13 -

CHAMPION: Longitudinal analysis(2)

Return to:

The American Journal of Cardiology

« Prev

Next Speaker »
Click Figure to Enlarge

Auto-play

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Cardiology

Print This Page

Abraham - Figure 13

CHAMPION Longitudal Analysis (2): Randomized and Open Access

As described in Figure 13, the control patients in CHAMPION were followed for an average of 17.5 months in the randomized portion of the trial, and then for an additional open-access follow-up averaging 13 months, during which the control patients transitioned to providing information from the hemodynamic monitoring device.^[12] As shown in Figure 13, during this follow-up with active PAP monitoring these former control patients demonstrated a 48% reduction in HF hospitalizations.

So, in summary, the CHAMPION Trial results have demonstrated that PAP-guided HF management can have a very significant effect on reducing the risk of HF hospitalizations, and that this occurs regardless of the patient’s LVEF. It occurs in important subpopulations of HF patients, such as those with common HF comorbidities, and it also occurs in those patients who are well treated with guideline directed medical therapy (GDMT).

Abraham WT. Am J Cardiol. 2015; 00.

References

[12]

Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet, published online November 8, 2015.

« Prev

Next Activity »